PortfoliosLab logoPortfoliosLab logo
GH vs. TMDX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GH vs. TMDX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Guardant Health, Inc. (GH) and TransMedics Group, Inc. (TMDX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GH achieves a 27.44% return, which is significantly higher than TMDX's -43.73% return.


GH

1D
0.80%
1M
48.60%
YTD
27.44%
6M
25.32%
1Y
209.19%
3Y*
58.99%
5Y*
2.00%
10Y*

TMDX

1D
1.36%
1M
-31.56%
YTD
-43.73%
6M
-51.72%
1Y
-44.77%
3Y*
-2.60%
5Y*
22.00%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GH vs. TMDX - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
GH
Guardant Health, Inc.
27.44%234.34%12.94%-0.55%-72.81%-22.39%64.93%17.80%
TMDX
TransMedics Group, Inc.
-43.73%95.11%-21.01%27.88%222.13%-3.72%4.68%-14.98%

Correlation

The correlation between GH and TMDX is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.28

Correlation (5Y)
Calculated over the trailing 5-year period

0.36

Correlation (All Time)
Calculated using the full available price history since May 3, 2019

0.32

The correlation between GH and TMDX shifts across timeframes, from 0.17 (1 year) to 0.36 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

GH:

$17.09B

TMDX:

$2.48B

EPS

GH:

-$3.40

TMDX:

$4.34

PS Ratio

GH:

15.34

TMDX:

4.26

Total Revenue (TTM)

GH:

$1.08B

TMDX:

$635.89M

Gross Profit (TTM)

GH:

$701.01M

TMDX:

$375.74M

EBITDA (TTM)

GH:

-$411.42M

TMDX:

$125.51M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GH vs. TMDX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GH
GH Risk / Return Rank: 9595
Overall Rank
GH Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
GH Sortino Ratio Rank: 9595
Sortino Ratio Rank
GH Omega Ratio Rank: 9494
Omega Ratio Rank
GH Calmar Ratio Rank: 9494
Calmar Ratio Rank
GH Martin Ratio Rank: 9393
Martin Ratio Rank

TMDX
TMDX Risk / Return Rank: 99
Overall Rank
TMDX Sharpe Ratio Rank: 99
Sharpe Ratio Rank
TMDX Sortino Ratio Rank: 1111
Sortino Ratio Rank
TMDX Omega Ratio Rank: 1212
Omega Ratio Rank
TMDX Calmar Ratio Rank: 1010
Calmar Ratio Rank
TMDX Martin Ratio Rank: 11
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GH vs. TMDX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and TransMedics Group, Inc. (TMDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GHTMDXDifference

Sharpe ratio

Return per unit of total volatility

3.61

-0.77

+4.39

Sortino ratio

Return per unit of downside risk

4.18

-0.97

+5.16

Omega ratio

Gain probability vs. loss probability

1.54

0.88

+0.66

Calmar ratio

Return relative to maximum drawdown

6.68

-0.79

+7.47

Martin ratio

Return relative to average drawdown

16.63

-2.02

+18.65

GH vs. TMDX - Sharpe Ratio Comparison

The current GH Sharpe Ratio is 3.61, which is higher than the TMDX Sharpe Ratio of -0.77. The chart below compares the historical Sharpe Ratios of GH and TMDX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GHTMDXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.61

-0.77

+4.39

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.03

0.31

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

0.29

0.24

+0.06

Drawdowns

GH vs. TMDX - Drawdown Comparison

The maximum GH drawdown since its inception was -91.03%, which is greater than TMDX's maximum drawdown of -73.69%. Use the drawdown chart below to compare losses from any high point for GH and TMDX.


Loading charts...

Drawdown Indicators


GHTMDXDifference

Max Drawdown

Largest peak-to-trough decline

-91.03%

-73.69%

-17.34%

Max Drawdown (1Y)

Largest decline over 1 year

-32.98%

-58.76%

+25.78%

Max Drawdown (3Y)

Largest decline over 3 years

-59.79%

-67.79%

+8.00%

Max Drawdown (5Y)

Largest decline over 5 years

-87.84%

-67.79%

-20.05%

Current Drawdown

Current decline from peak

-27.32%

-61.13%

+33.81%

Average Drawdown

Average peak-to-trough decline

-51.69%

-31.78%

-19.91%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.26%

22.84%

-9.58%

Volatility

GH vs. TMDX - Volatility Comparison

The current volatility for Guardant Health, Inc. (GH) is 18.50%, while TransMedics Group, Inc. (TMDX) has a volatility of 29.66%. This indicates that GH experiences smaller price fluctuations and is considered to be less risky than TMDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GHTMDXDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.50%

29.66%

-11.16%

Volatility (6M)

Calculated over the trailing 6-month period

37.97%

43.79%

-5.82%

Volatility (1Y)

Calculated over the trailing 1-year period

58.39%

58.12%

+0.27%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.65%

72.03%

-4.38%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

68.15%

71.76%

-3.61%

Dividends

GH vs. TMDX - Dividend Comparison

Neither GH nor TMDX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

GH vs. TMDX - Financials Comparison

This section allows you to compare key financial metrics between Guardant Health, Inc. and TransMedics Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
301.67M
173.93M
(GH) Total Revenue
(TMDX) Total Revenue
Values in USD except per share items

GH vs. TMDX - Profitability Comparison

The chart below illustrates the profitability comparison between Guardant Health, Inc. and TransMedics Group, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

55.0%60.0%65.0%70.0%75.0%20222023202420252026
65.2%
58.2%
Portfolio components
GH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported a gross profit of 196.75M and revenue of 301.67M. Therefore, the gross margin over that period was 65.2%.

TMDX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported a gross profit of 101.16M and revenue of 173.93M. Therefore, the gross margin over that period was 58.2%.

GH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported an operating income of -121.35M and revenue of 301.67M, resulting in an operating margin of -40.2%.

TMDX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported an operating income of 13.30M and revenue of 173.93M, resulting in an operating margin of 7.6%.

GH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported a net income of -112.08M and revenue of 301.67M, resulting in a net margin of -37.2%.

TMDX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported a net income of 7.32M and revenue of 173.93M, resulting in a net margin of 4.2%.


Frequently Asked Questions


GH and TMDX have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TMDX has higher volatility (29.66%) compared to GH (18.50%). In terms of maximum drawdown, GH dropped -91.03% vs TMDX's -73.69%.

GH currently has the higher Sharpe Ratio (3.61 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GH and TMDX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer